SCHEMBL6774110

SCHEMBL6774110

O=C(c1ccccc1OCc1ccccc1)N(Cc1cccnc1)Cc1ccccc1-c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SGMS2 Q8NHU3 1/20 0.50
▸ SLC1A5 Q15758 1/20 0.46
▸ HTR1A P08908 1/20 0.46
▸ DRD2 P14416 1/20 0.46
▸ ALDH1A1 P00352 2/20 0.45
▸ POLB P06746 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ CYP11B1 P15538 2/20 0.44
▸ CYP11B2 P19099 2/20 0.44
▸ PTGER1 P34995 1/20 0.44
▸ PTGER4 P35408 1/20 0.44
▸ PTGER3 P43115 1/20 0.44
▸ PTGER2 P43116 1/20 0.44
▸ CYP19A1 P11511 1/20 0.44
▸ PDCD1 Q15116 4/20 0.44
▸ CD274 Q9NZQ7 4/20 0.44
▸ PDK1 Q15118 1/20 0.44
▸ IKBKB O14920 1/20 0.43
▸ MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6780767 0.91 ALDH1A1 (0.46) ALDH1A1HTTKMT2APDK1MAPT
SCHEMBL6777732 0.89 LPAR1 (0.52) ALDH1A1POLBHTTKMT2APDK1
SCHEMBL6778426 0.83 KMT2A (0.48) ALDH1A1HTTKMT2AMAPTKCNA5
SCHEMBL6780567 0.82 GPBAR1 (0.49) ALDH1A1POLBHTTKMT2AMAPT
SCHEMBL6783999 0.81 PTGER1 (0.47) SGMS2HTTPTGER1PTGER4PTGER3
SCHEMBL6778233 0.80 HTT (0.51) ALDH1A1POLBHTTKMT2APDCD1
SCHEMBL14609971 0.80 TRPM8 (0.57) SGMS2SLC1A5HTR1ADRD2ALDH1A1
SCHEMBL6785117 0.78 TSHR (0.49) SGMS2ALDH1A1POLBHTTKMT2A
SCHEMBL6785255 0.78 LMNA (0.51) ALDH1A1POLBHTTKMT2AMAPT
SCHEMBL7673590 0.78 ALDH1A1 (0.46) ALDH1A1HTTKMT2AMAPTKCNA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6780883-B2 ANTICHOLESTEROL AGENTS; CARDIOVASCULAR DISORDERS; ANTILIPEMIC AGENTS; RESTENOSIS; DIETETICS WARNER-LAMBERT COMPANY 2004-08-24 — — US claimed
US-20020156281-A1 Amide inhibitors of microsomal triglyceride transfer protein BOOTH RICHARD JOHN (US) 2002-10-24 — — US claimed
US-6780883-B2 ANTICHOLESTEROL AGENTS; CARDIOVASCULAR DISORDERS; ANTILIPEMIC AGENTS; RESTENOSIS; DIETETICS WARNER-LAMBERT COMPANY 2004-08-24 — — US disclosed
US-20020156281-A1 Amide inhibitors of microsomal triglyceride transfer protein BOOTH RICHARD JOHN (US) 2002-10-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020156281-A1 Amide inhibitors of microsomal triglyceride transfer protein CETP, MTTP, LCAT SGMS2 459/4885SLC1A5 478/4885HTR1A 2817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback